Micromet, Inc. (NASDAQ: MITI) announced today that preliminary data from an ongoing phase 1 trial on MT103 will be presented at the 11th Congress of the European Hematology Association (EHA). The abstract has been selected by the EHA for oral forum presentation scheduled for June 17, 2006, at 11:15 AM CET / 05:15 AM EST by Dr. Ralf Bargou, the principal investigator of the trial from the University of Wuerzburg, Germany. In addition, data will be presented as a poster on June 16 at 5:45 PM CET / 11:45 AM EST.
